Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited announced the retirement of its board chair, Mr. Michael Alscher, effective April 30, 2025. Mr. Alscher has been with ACL since 2015, and the company expressed gratitude for his leadership. Mr. Mark Haberlin, currently the Chair of ACL’s Audit and Risk Committee, will serve as Interim Chair. This transition is part of ACL’s succession planning to ensure the board’s composition aligns with its strategic goals. The change in leadership is expected to support ACL’s ongoing strategy and operations, potentially impacting its industry positioning and stakeholder relations.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a leading private provider of pathology services in Australia. The company operates NATA accredited laboratories that perform a wide range of pathology tests for various clients, including doctors, specialists, patients, hospitals, and corporate clients. ACL is one of the largest private hospital pathology businesses in the country, focusing on combining talented personnel with medical and scientific leadership to enhance decision-making that saves and improves patients’ lives.
YTD Price Performance: -13.24%
Average Trading Volume: 944,794
Technical Sentiment Signal: Buy
Current Market Cap: A$585.8M
See more data about ACL stock on TipRanks’ Stock Analysis page.